A BYD retail store in Fukuoka, Japan. Photo: VCG Japan will sharply reduce purchase subsidies for several electric vehicles sold by China’s BYD under revised rules that place greater weight on domestic production, locally sourced batteries and supply-chain resilience. The change underscores how governments are using EV incentives not only to spur adoption but also to steer investment and technolog...
A BYD retail store in Fukuoka, Japan. Photo: VCG Japan will sharply reduce purchase subsidies for several electric vehicles sold by China’s BYD under revised rules that place greater weight on domestic production, locally sourced batteries and supply-chain resilience. The change underscores how governments are using EV incentives not only to spur adoption but also to steer investment and technology supply chains — an approach that could reshape competition in major auto markets as Chinese automakers expand overseas.
Yahoo Finance Senior Reporter Brooke DiPalma takes a closer look at some of Tuesday morning's trending tickers and stories, including some of the latest deals and investments.Nvidia (NVDA) is investing $2 billion in Marvell (MRVL).Biogen (BIIB) is buying Apellis Pharmaceuticals (APLS) for $5.6 billion.Eli Lilly (LLY) is set to buy sleep-drug maker Centessa (CNTA) for up to $7.8 billion.
Yahoo Finance Senior Reporter Brooke DiPalma takes a closer look at some of Tuesday morning's trending tickers and stories, including some of the latest deals and investments.Nvidia (NVDA) is investing $2 billion in Marvell (MRVL).Biogen (BIIB) is buying Apellis Pharmaceuticals (APLS) for $5.6 billion.Eli Lilly (LLY) is set to buy sleep-drug maker Centessa (CNTA) for up to $7.8 billion.
Critics say exemption exploits White House’s ‘self-made gas crisis’, and could doom the rare Rice’s whale Sign up for the Breaking News US email to get newsletter alerts in your inbox A US government panel on Tuesday exempted oil and gas drilling in the Gulf of Mexico from the Endangered Species Act (ESA), a move which critics say could doom a rare whale species and harm other marine life . The En...
Critics say exemption exploits White House’s ‘self-made gas crisis’, and could doom the rare Rice’s whale Sign up for the Breaking News US email to get newsletter alerts in your inbox A US government panel on Tuesday exempted oil and gas drilling in the Gulf of Mexico from the Endangered Species Act (ESA), a move which critics say could doom a rare whale species and harm other marine life . The Endangered Species Committee – which had not convened in more than three decades – voted to approve the request for the ESA exemption at the request of the defense secretary, Pete Hegseth . Continue reading...
Alexey_Fedoren Piper Sandler has initiated Regeneron Pharmaceuticals ( REGN ) at overweight saying that it expects continued growth in Dupixent (dupilumab) sales as well as "several high-potential pipeline assets." The firm set a price target of $875 (~17% upside based on March 30 close). Analyst Biren Amin is projecting Dupixent sales to surge ~50% from 2025-2030, reaching about ~$20B by the end ...
Alexey_Fedoren Piper Sandler has initiated Regeneron Pharmaceuticals ( REGN ) at overweight saying that it expects continued growth in Dupixent (dupilumab) sales as well as "several high-potential pipeline assets." The firm set a price target of $875 (~17% upside based on March 30 close). Analyst Biren Amin is projecting Dupixent sales to surge ~50% from 2025-2030, reaching about ~$20B by the end of that period. He noted that the company has done well to ameliorate competition from standard-dose Eylea (aflibercept) with Eylea HD, as the latter now accounts for 47% of the franchise's sales in the US. Amin added that loss of sales to biosimilars should be lessened by an anticipated Q2 approval of a prefilled syringe ("could serve as the next catalyst for REGN shares") and the recent approval of monthly dosing. Amin called Regeneron's pipeline "underappreciated," emphasizing its Factor XI antibody program. He models peak risk-adjusted sales of (REGN7508/REGN9933) of $2.7B compared to the consensus of $1.1B. "By decoupling efficacy from bleeding risk, this next-generation anticoagulation approach has the potential to unlock the ~50% of the market currently untreated due to safety concerns." Elsewhere in the pipeline, other potential long-term revenue drivers are "fianlimab in metastatic melanoma, cemidisiran in immunology, and cat/birch allergy programs." More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript Regeneron: Fairly Valued Now After A Stellar Upswing Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Regeneron-licensed obesity drug shows positive phase 3 results in China FDA issues draft guidance to relax testing rules to encourage biosimilar drugs
frantic00 After three days in the red, weighed down by the volatility in the energy markets and the fluid geopolitical climate, shares of Norwegian Cruise Line Holdings ( NCLH ) are grinding higher, buoyed by a retreat in oil prices and an endorsement from Stifel. In a note to clients after the company’s investor event, Stifel analyst Steven Wieczynski believes investors are incorrectly assuming m...
frantic00 After three days in the red, weighed down by the volatility in the energy markets and the fluid geopolitical climate, shares of Norwegian Cruise Line Holdings ( NCLH ) are grinding higher, buoyed by a retreat in oil prices and an endorsement from Stifel. In a note to clients after the company’s investor event, Stifel analyst Steven Wieczynski believes investors are incorrectly assuming management is “talking down yield guidance for the remainder of 2026." “In our view, NOTHING (and we can’t say this loud enough) has changed versus when we met with [CEO John Chidsey] in mid-March,” Wieczynski says, noting that the company withheld yield guidance for the second half of this year to emphasize that Q3 will be the toughest from a yield perspective, with most of their inventory in weaker European and Alaskan markets. “It absolutely makes sense for NCLH to be conservative [with FY26 guidance]. With a new CEO plus an activist on the scene, why not just write off 2026 and give the company time to focus on 2027, as nothing really can be done at this point in 2026 given the elongated booking window of the cruise industry?” Wieczynski says. At issue is the company’s 2026 guidance and comments surrounding pressure on pricing and yields. During the earnings call with analysts , CFO Mark Kempa noted that Norwegian entered 2026 slightly behind an ideal booking curve in certain itineraries, “creating near-term pressure on pricing and yield, which is evidenced in guidance.” Accordingly, Norwegian now expects its net yield to contract ~1.6% as higher occupancy is offset by pricing pressures. For the balance of the year, net yields are expected to stabilize and “modestly improve” by 0.6%, bringing full-year net yields to approximately flat. As this conservatism likely spooked investors, Wieczynski believes this fueled a “significant dislocation” in the share price/valuation and that investors are overlooking two important factors in regard to NCLH. First, the company has adeq...
Nvidia (NASDAQ:NVDA) is back in a bear market, and with the $170 support level breaking down, the next stop might lie closer to $140 per share. Undoubtedly, that’d represent another 15% dip from current levels. And while shares have gone from cheap to cheaper in recent weeks, with shares now going for 33.6 times trailing ... Why I’m Staying Cautious on NVIDIA—and the Stocks I Prefer Instead
Nvidia (NASDAQ:NVDA) is back in a bear market, and with the $170 support level breaking down, the next stop might lie closer to $140 per share. Undoubtedly, that’d represent another 15% dip from current levels. And while shares have gone from cheap to cheaper in recent weeks, with shares now going for 33.6 times trailing ... Why I’m Staying Cautious on NVIDIA—and the Stocks I Prefer Instead